Covered recipient · General Payments record
ALINA KLUK
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2024–2025
$540.11
- Reported across 23 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $361.91 | 15 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme Corporation | $71.65 | 3 |
| Amgen Inc. | $68.58 | 3 |
| Exact Sciences Corporation | $46.49 | 2 |
| Lilly USA, LLC | $34.84 | 1 |
| Axsome Therapeutics, Inc. | $32.08 | 1 |
| Abbott Laboratories | $26.67 | 1 |
| Novo Nordisk AS | $22.54 | 1 |
| ABBVIE INC. | $20.38 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.86 | 1 |
| KYOWA KIRIN, INC. | $18.82 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $26.67 | 12/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1241000343 | CMS |
| ABBVIE INC. | $20.38 | 02/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1202215189 | CMS |
| Amgen Inc. | $21.87 | 08/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228343162 | CMS |
| Amgen Inc. | $22.80 | 11/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228343164 | CMS |
| Amgen Inc. | $23.91 | 12/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228343160 | CMS |
| Axsome Therapeutics, Inc. | $32.08 | 04/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1235701339 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.86 | 12/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1223060490 | CMS |
| Exact Sciences Corporation | $26.67 | 10/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1235232343 | CMS |
| Exact Sciences Corporation | $19.82 | 12/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1235232345 | CMS |
| KYOWA KIRIN, INC. | $18.82 | 04/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1222091184 | CMS |
| Lilly USA, LLC | $34.84 | 08/26/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186501401 | CMS |
| Merck Sharp & Dohme LLC | $27.48 | 01/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238256693 | CMS |
| Merck Sharp & Dohme LLC | $18.41 | 03/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238014220 | CMS |
| Merck Sharp & Dohme LLC | $25.76 | 05/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238256691 | CMS |
| Novo Nordisk Inc | $22.54 | 08/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188176333 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2024, 2025
- Source files
- Dataset page · Bulk file · PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.